Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The proto-oncogene c-myc in hematopoietic development and leukemogenesis

Abstract

The proto-oncogene c-myc has been shown to play a pivotal role in cell cycle regulation, metabolism, apoptosis, differentiation, cell adhesion, and tumorigenesis, and participates in regulating hematopoietic homeostasis. It is a transcription regulator that is part of an extensive network of interacting factors. Most probably, different biological responses are elicited by different overlapping subsets of c-Myc target genes, both induced and suppressed. Results obtained from studies employing mouse models are consistent with the need for at least one, and possibly two, mutations in addition to deregulated c-myc for malignant tumor formation. Repression of c-myc is required for terminal differentiation of many cell types, including hematopoietic cells. It has been shown that deregulated expression of c-myc in both M1 myeloid leukemic cells and normal myeloid cells derived from murine bone marrow, not only blocked terminal differentiation and its associated growth arrest, but also induced apoptosis, which is dependent on the Fas/CD95 pathway. There is evidence to suggest that the CD95/Fas death receptor pathway is an integral part of the apoptotic response associated with the end of the normal terminal myeloid differentiation program, and that deregulated c-myc expression can activate this signaling pathway prematurely. The ability of egr-1 to promote terminal myeloid differentiation when co-expressed with c-myc, and of c-fos to partially abrogate the block imparted by deregulated c-myc on myeloid differentiation, make these two genes candidate tumor suppressors. Several different transcription factors have been implicated in the down-regulation of c-myc expression during differentiation, including C/EBPα, CTCF, BLIMP-1, and RFX1. Alterations in the expression and/or function of these transcription factors, or of the c-Myc and Max interacting proteins, such as MM-1 and Mxi1, can influence the neoplastic process. Understanding how c-Myc controls cellular phenotypes, including the leukemic phenotype, should provide novel tools for designing drugs to promote differentiation and/or apoptosis of leukemic cells.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  • Adams JM, Harris AW, Strasser A, Ogilvy S, Cory S . 1999 Oncogene 18: 5268–5277

  • Alland L, Muhle R, Hou Jr H, Potes J, Chin L, Schreiber-Agur N, DePinho RA . 1997 Nature 387: 49–55

  • Amanullah A, Liebermann DA, Hoffman B . 2000 Oncogene 19: 2967–2977

  • Amanullah A, Liebermann DA, Hoffman B . 2002 Oncogene 21: 1600–1610

  • Amati B, Land H . 1994 Curr. Opin. Genet. Dev. 4: 102–108

  • Askew DS, Ashmun RA, Simmons BC, Cleveland JL . 1991 Oncogene 6: 1915–1922

  • Ayer DE, Eisenman N . 1993 Genes Dev. 7: 2110–2119

  • Ayer DE, Kretzner L, Eisenman RN . 1993 Cell 72: 211–222

  • Ayer DE, Lawrence QA, Eisenman RN . 1995 Cell 80: 767–776

  • Baudino TA, Cleveland JL . 2001 Mol. Cell. Biol. 21: 691–702

  • Beckmann AM, Wilce PA . 1997 Neurochem. Int. 4: 477–510

  • Beijersbergen RL, Hijmans EM, Zhu L, Bernards R . 1994 EMBO J. 13: 4080–4086

  • Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Macgrath I . 1993 Nat. Genet. 5: 56–61

  • Bhatia K, Spangler G, Hamdy N, Neri A, Brubaker G, Levin A, Macgrath I . 1995 Curr. Top. Microbiol. Immunol. 194: 389–398

  • Bissonnette RP, Echeverri F, Mahboubi A, Green DR . 1992 Nature 359: 552–554

  • Blackwell TK, Kretzner L, Backwood EM, Eisenman RN, Weintraub H . 1990 Science 250: 1149–1151

  • Boxer LM, Dang CV . 2001 Oncogene 20: 5595–5610

  • Brunner T, Kasibhatla S, Pinkoski MJ, Frutschi C, Yoo NJ, Echeverri F, Mahboubi A, Green DR . 2000 J. Biol. Chem. 275: 9767–9772

  • Cambier N, Zhang Y, Vairo G, Kosmopoulos K, Metcalf D, Nicola NA, Elefanty AG . 1999 Oncogene 18: 343–352

  • Cameron ER, Morton J, Johnston CJ, Irvine J, Bell M, Onions DE, Neil JC, Campbell M, Blyth K . 2000 Cell Death Differ. 7: 80–88

  • Chang DH, Angelin-Duclos C, Calame K . 2000 Nat. Immunol. 1: 169–176

  • Chen J, Willingham T, Margraf LR, Schreiber-Agus N, DePinho RA, Nisen PD . 1995 Nat. Med. 1: 638–643

  • Chen L, Smith L, Johnson MR, Wang K, Diasio RB, Smith JB . 2000 J. Biol. Chem. 275: 32227–32233

  • Claassen GF, Hann SR . 1999 Oncogene 18: 2925–2933

  • Crossen PE, Savage LM, Heaton DC, Morrison MJ . 1999 Cancer Genet. Cytogenet. 112: 144–148

  • Cultraro CM, Bino T, Segal S . 1997 Mol. Cell. Biol. 17: 2353–2359

  • Dang CV . 1999 Mol. Cell. Biol. 19: 1–11

  • Davies J, Badiani P, Weston K . 1999 Oncogene 18: 3643–3647

  • Delgardo MD, Chernukhin IV, Bigas A, Klenova EM, Leon J . 1999 FEBS Lett. 444: 5–10

  • Eischen CM, Woo D, Roussel MF, Cleveland JL . 2001 Mol. Cell. Biol. 21: 5063–5070

  • Elliott K, Ge K, Du W, Prendergast GC . 2000 Oncogene 19: 4669–4684

  • Evan GI, Littlewood TD . 1993 Curr. Opin. Genet. Dev. 3: 44–49

  • Fanidi A, Harrington EA, Evan GI . 1992 Nature 359: 554–556

  • Fecho K, Bentley SA, Cohen PL . 1998 Cell Immunol. 188: 19–32

  • Feinberg A . 2001 Proc. Natl. Acad. Sci. USA 98: 392–394

  • Felsher DW, Bishop JM . 1999a Proc. Natl. Acad. Sci. USA 96: 3940–3944

  • Felsher DW, Bishop JM . 1999b Mol. Cell 4: 199–207

  • Foley KP, McArthur GA, Queva C, Hurlin PJ, Soriano P, Eisenman RN . 1998 EMBO J. 17: 774–785

  • Freytag SO . 1988 Mol. Cell. Biol. 8: 1614–1624

  • Fujioka Y, Taira T, Maeda Y, Tanaka S, Nishihara H, Iguchi-Ariga SM, Nagashima K, Ariga H . 2001 J. Biol. Chem. 276: 45137–45144

  • Genestier L, Kasibhatla S, Brunner T, Green DR . 1999 J. Exp. Med. 189: 231–239

  • Gu W, Bhatia K, MacGrath IT, Dang CV, Dalla-Favera R . 1994 Science 264: 251–254

  • Harper SE, Qiu Y, Sharp PA . 1996 Proc. Natl. Acad. Sci. USA 93: 8536–8540

  • Hassig CA, Fleischer TC, Billin AN, Schreiber SL, Ayer DE . 1997 Cell 89: 341–347

  • Haupt Y, Harris AW, Adams JM . 1993 Int. J. Cancer 55: 623–629

  • Henriksson M, Luscher G . 1996 Adv. Cancer Res. 68: 110–182

  • Hoffman B, Liebermann DA . 1998 Oncogene 17: 3351–3357

  • Hoffman B, Liebermann DA, Selvakumaran M, Nguyen HQ . 1996 Curr. Top. Microbiol. Immunol. 211: 17–27

  • Hoffman-Liebermann B, Liebermann DA . 1991 Mol. Cell. Biol. 11: 2375–2381

  • Hurlin PJ, Queva C, Koshinen PJ, Steingrimsson E, Ayer DE, Copeland NG, Jenkins NA, Eisenman RN . 1995 EMBO J. 14: 5646–5659

  • Hurlin PJ, Queva C, Eisenman RN . 1997 Genes Dev. 11: 44–58

  • Johansen LM, Iwama A, Lodie TA, Sasaki K, Felsher DW, Golub TR, Tenen DG . 2001 Mol. Cell. Biol. 21: 3789–3806

  • Koshinen PJ, Ayer DE, Eisenman RN . 1995 Cell Growth Differ. 6: 623–629

  • Krishnaraju K, Nguyen HQ, Liebermann DA, Hoffman B . 1995 Mol. Cell. Biol. 15: 5499–5507

  • Krishnaraju K, Hoffman B, Liebermann DA . 1998 Blood 92: 1957–1966

  • Krishnaraju K, Hoffman B, Liebermann DA . 2001 Blood 97: 1298–1305

  • Laherty D, Yang W, Sun J, Davie JR, Seto E, Eisenman RN . 1997 Cell 89: 349–356

  • Lahox EG, Xu L, Schreiber-Agus N, DePinho RA . 1994 Proc. Natl. Acad. Sci. USA 91: 5503–5507

  • Landshulz WH, Johnson PF, McKnight SL . 1988 Science 240: 1759–1764

  • Li LH, Nerlov C, Prendergast G, McGregor D, Ziff EB . 1994 EMBO J. 13: 4070–4079

  • Liebermann DA, Gregory B, Hoffman B . 1998 Int. J. Onc. 12: 685–700

  • Lindeman GJ, Harris AW, Bath ML, Eisenman RN, Adams JM . 1995 Oncogene 10: 1013–1017

  • Lord KA, Abdollahi A, Hoffman-Liebermann B, Liebermann DA . 1993 Mol. Cell. Biol. 13: 841–851

  • McKenna SL, Cotter TG . 1997 Adv. Cancer Res. 71: 121–164

  • McMahon SB, Monroe JG . 1996 J. Leukoc. Biol. 2: 159–166

  • McMahon SB, Wood MA, Cole MD . 2000 Mol. Cell. Biol. 20: 556–562

  • Metcalf D . 1989 Nature 339: 27–30

  • Metcalf D . 1991 Science 254: 529–533

  • Mori K, Maeda Y, Kitaura H, Taira T, Iguchi-Ariga SMM, Ariga H . 1998 J. Biol. Chem. 273: 29794–29800

  • Murre C, Schonleber-McCaw P, Baltimore D . 1989 Cell 56: 777–783

  • Nesbit CE, Tersak JM, Prochownik EV . 1999 Oncogene 18: 3004–3016

  • Nguyen H, Hoffman-Liebermann B, Liebermann DA . 1993 Cell 72: 197–209

  • O'Malley F, Rayeroux K, Cole-Sinclair M, Tong M, Campbell LJ . 1999 Cancer Genet. Cytogenet. 109: 123–125

  • Ohlsson R, Renkawitz R, Lobanenkov V . 2001 Trends Genet. 17: 520–527

  • Packham G, Cleveland JL . 1995 Biochim. Biophys. Acta 1242: 11–28

  • Quesenberry PJ . 1990 Hematology, Williams WJ, Beutler E, Erslev AJ and Lichtman MA (eds) New York: McGraw-Hill pp 129–147

  • Rabbitts TH, Hamlyn PH, Baer R . 1983 Nature 306: 760–765

  • Rao G, Alland L, Guida P, Schreiber-Agus N, Chen K, Chin L, Rochelle JM, Seldin MF, Skoultchi AI, DePinho RA . 1996 Oncogene 12: 1165–1172

  • Rasko JE, Klenova EM, Leon J, Filippova GN, Loukinov DI, Vatolin S, Robinson AF, Hu YJ, Ulmer J, Ward MD, Pugacheva EM, Neiman PE, Morse III HC, Collins SJ, Lobanenkov VV . 2001 Cancer Res. 61: 6002–6007

  • Roussel MF, Ashmun RA, Sherr CJ, Eisenman RN, Ayer DE . 1996 Mol. Cell. Biol. 16: 2796–2801

  • Ryan KM, Birnie GD . 1997 Oncogene 14: 2835–2843

  • Sachs L . 1987 Science 238: 1374–1379

  • Sakamuro D, Prendergast GC . 1999 Oncogene 18: 2942–2954

  • Schmidt M, Nazarov V, Stevens L, Watson R, Wolff L . 2000 Mol. Cell. Biol. 20: 1970–1981

  • Schreiber-Agus N, Chin L, Chen K, Torres R, Rao G, Guida P, Skoultchi A, DePinho RA . 1995 Cell 80: 777–786

  • Schreiber-Agus N, Meng Y, Hoang T, Hou Jr J, Chen K, Greenberg R, Cordon-Cardo C, Lee H-W, DePinho RA . 1998 Nature 393: 483–487

  • Selvakumaran M, Lin HK, TjinThamSjin R, Reed JC, Liebermann DA, Hoffman B . 1994 Mol. Cell. Biol. 14: 2352–2360

  • Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP, Green DR . 1992 Science 257: 212–214

  • Strasser A, Harris AW, Bath ML, Cory S . 1990 Nature 348: 331–333

  • Traver D, Akashi K, Weissman IL, Lagasse E . 1998 Immunity 9: 47–57

  • Wu SJ, Pena A, Korcz A, Soprano DR, Soprano KJ . 1996 Oncogene 12: 621–629

  • Zervos AS, Gyuris J, Brent R . 1993 Cell 72: 223–232

  • Zhang D-E, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG . 1997 Proc. Natl. Acad. Sci. USA 94: 569–574

  • Zornig M, Grzeschiczek A, Kowalski M-B, Hartmann K-U, Moroy T . 1995 Oncogene 10: 2397–2401

Download references

Acknowledgements

This research was supported by National Institute of Health Grant RO1 CA81168 (to B Hoffman).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Barbara Hoffman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoffman, B., Amanullah, A., Shafarenko, M. et al. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 21, 3414–3421 (2002). https://doi.org/10.1038/sj.onc.1205400

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205400

Keywords

This article is cited by

Search

Quick links